BCL2 and acute myeloid leukemia: Combining FLT3 inhibitors with VTX could be a useful strategy to overcome BCL-2 inhibitor resistance between FLT3-mutated AML patients and to prevent the appearance of FLT3-mutated subclones in patients with no detectable FLT3 mutation.